Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Genetic risk in telomere biology disorders: it adds up
Tanner O. Monroe
Tanner O. Monroe
Published August 15, 2025
Citation Information: J Clin Invest. 2025;135(16):e195921. https://doi.org/10.1172/JCI195921.
View: Text | PDF
Commentary

Genetic risk in telomere biology disorders: it adds up

  • Text
  • PDF
Abstract

For many conditions, genotyping aids in clinical decision making. However, interpreting the clinical significance of genetic variants remains challenging, in part because a single risk variant does not always lead to disease, and variant carriers experience variable outcomes. One hypothesis underlying these phenomena, which are known as incomplete penetrance and variable expressivity, respectively, is that additional common genetic variation beyond the primary variant influences the presence and severity of disease. In this issue of JCI, Poeschla et al. present a compelling argument that common variants linked to telomere length act together with high-risk telomere biology disorder variants to scale outcomes. These data support a model in which many variants interact to shape cumulative risk.

Authors

Tanner O. Monroe

×

Figure 1

Polygenic background modifies disease probability in carriers of rare pathogenic telomere biology disorder (TBD) variants.

Options: View larger image (or click on image) Download as PowerPoint
Polygenic background modifies disease probability in carriers of rare pa...
Rare telomere biology disorder (TBD) pathogenic genetic variants do not always result in overt disease, and affected individuals exhibit considerable phenotypic variability — from relatively minor to severe. One hypothesis is that background genetic variation beyond the primary pathogenic variant contributes to this variety of outcomes. (A) Common variants associated with mean telomere length through a GWAS performed by Poeschla and colleagues can be used to generate polygenic scores (PGS) that represent telomere length predisposition. (B) They found that this score shifts the total genetic liability in individuals who also carry rare TBD pathogenic variants, influencing both the probability of developing TBD and disease severity. Individuals with a a high-risk PGS (short telomere predisposition; top) have increased risk of crossing a TBD liability threshold, often manifesting as early onset disease, while those with a low-risk PGS (long telomere predisposition; bottom) are less likely to manifest disease, despite carrying the same rare variant. Importantly, the genetic liability threshold for TBD is only relevant in the context a pathogenic variant, and there are some individuals to the left of the liability threshold who do not have severe disease, indicating the complex genetic architecture yet to be uncovered.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts